APOC3 and type 2 diabetes mellitus: Given the fact that apoC-III levels are increased in people with type 2 diabetes [76] and that fibrates reduce apoC-III levels [75, 77], it is surprising that so far no data exist on a potential link between the reduction of apoC-III and CVD outcomes from randomized clinical trials of fibrates.